A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. / Zeng, Yuan; Mayne, Nicholas; Yang, Chi Fu Jeffrey; D’Amico, Thomas A.; Ng, Calvin S.H.; Liu, Chia chuan; Petersen, René Horsleben; Rocco, Gaetano; Brunelli, Alessandro; Liu, Jun; Liu, Yang; Huang, Weizhe; He, Jiaxi; Wang, Wei; Jiang, Long; Cui, Fei; Wang, Wenjun; Liang, Wenhua; He, Jianxing; the AME Thoracic Surgery Collaborative Group.
I: Annals of Surgical Oncology, Bind 26, Nr. 7, 2019, s. 2053-2062.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer
AU - Zeng, Yuan
AU - Mayne, Nicholas
AU - Yang, Chi Fu Jeffrey
AU - D’Amico, Thomas A.
AU - Ng, Calvin S.H.
AU - Liu, Chia chuan
AU - Petersen, René Horsleben
AU - Rocco, Gaetano
AU - Brunelli, Alessandro
AU - Liu, Jun
AU - Liu, Yang
AU - Huang, Weizhe
AU - He, Jiaxi
AU - Wang, Wei
AU - Jiang, Long
AU - Cui, Fei
AU - Wang, Wenjun
AU - Liang, Wenhua
AU - He, Jianxing
AU - the AME Thoracic Surgery Collaborative Group
PY - 2019
Y1 - 2019
N2 - Background: Models for predicting the survival outcomes of stage I non-small-cell lung cancer (NSCLC) defined by the newly released 8th edition TNM staging system are scarce. This study aimed to develop a nomogram for predicting the cancer-specific survival (CSS) of these patients and identifying individuals with a higher risk for CSS. Methods: A total of 30,475 NSCLC cases were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified and integrated the risk factors to build a nomogram. The model was subjected to bootstrap internal validation with the SEER database, and external validation with a multicenter cohort of 1133 patients from China. The difference in the impact of adjuvant chemotherapy on model-defined high- and low-risk patients was examined using the National Cancer Database (NCDB). Results: Eight independent prognostic factors were identified and integrated into the model. The calibration curves showed good agreement. The concordance index (C-index) of the nomogram was higher than that of the staging system (IA1, IA2, IA3, and IB) (internal validation set 0.63 vs. 0.56; external validation set 0.66 vs. 0.55; both p < 0.01). Specifically, 21.7% of stage IB patients (7.5% of all stage I) were categorized into the high-risk group (score > 30). There was a significant interaction effect between the adjuvant chemotherapy and risk groups in the NCDB cohort (p = 0.003). Conclusions: We established a practical nomogram to predict CSS for 8th edition stage I NSCLC. A prospective study is warranted to determine its role in identifying adjuvant chemotherapy candidates.
AB - Background: Models for predicting the survival outcomes of stage I non-small-cell lung cancer (NSCLC) defined by the newly released 8th edition TNM staging system are scarce. This study aimed to develop a nomogram for predicting the cancer-specific survival (CSS) of these patients and identifying individuals with a higher risk for CSS. Methods: A total of 30,475 NSCLC cases were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified and integrated the risk factors to build a nomogram. The model was subjected to bootstrap internal validation with the SEER database, and external validation with a multicenter cohort of 1133 patients from China. The difference in the impact of adjuvant chemotherapy on model-defined high- and low-risk patients was examined using the National Cancer Database (NCDB). Results: Eight independent prognostic factors were identified and integrated into the model. The calibration curves showed good agreement. The concordance index (C-index) of the nomogram was higher than that of the staging system (IA1, IA2, IA3, and IB) (internal validation set 0.63 vs. 0.56; external validation set 0.66 vs. 0.55; both p < 0.01). Specifically, 21.7% of stage IB patients (7.5% of all stage I) were categorized into the high-risk group (score > 30). There was a significant interaction effect between the adjuvant chemotherapy and risk groups in the NCDB cohort (p = 0.003). Conclusions: We established a practical nomogram to predict CSS for 8th edition stage I NSCLC. A prospective study is warranted to determine its role in identifying adjuvant chemotherapy candidates.
U2 - 10.1245/s10434-019-07318-7
DO - 10.1245/s10434-019-07318-7
M3 - Journal article
C2 - 30900105
AN - SCOPUS:85063214431
VL - 26
SP - 2053
EP - 2062
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 7
ER -
ID: 226258755